Eye trauma plus sickle cell trait (SCT) is a combination every emergency physician, primary care clinician, and sports-medicine provider should treat as time-critical. The risk is glaucoma post-hyphema — a rapid rise in intraocular pressure (IOP) following bleeding into the anterior chamber — and patients with SCT develop it more readily than the general population.
Why SCT changes the rules. Red cells with HbS sickle in the relatively hypoxic, acidic environment of the anterior chamber. Sickled cells obstruct the trabecular meshwork, IOP climbs, and the optic nerve is at risk. Some standard glaucoma medications — particularly carbonic anhydrase inhibitors — can worsen sickling in the anterior chamber. Drug choice matters.
What to do at first contact: 1. Refer to ophthalmology emergently. Not later today. Now. 2. While arranging transfer, protect the eye — rigid shield, no patching that applies pressure, head of bed elevated to 30°. 3. Communicate the patient's SCT status to the ophthalmologist explicitly. They will choose IOP-lowering agents that are safe in sickling conditions. 4. Limit activity, restrict Valsalva, address pain and nausea (vomiting raises IOP).
What ophthalmology will manage:
- Bedrest, sedation if rebleeding risk is high.
- Topical cycloplegics and corticosteroids per protocol.
- IOP monitoring multiple times a day.
- Anti-fibrinolytics in select cases.
- Surgical intervention (anterior chamber washout) if IOP cannot be controlled within 24 hours — earlier in SCT than in non-SCT patients.
Counseling after stabilization: any patient who learns they have SCT in the context of an eye injury deserves a follow-up conversation. Cover protective eyewear in sport, the (rare) other SCT-related risks, and reproductive implications.
The line I tell residents: In a patient with SCT, every hyphema is a high hyphema until ophthalmology says otherwise.
— Dr. Rob
📄 Resource: CDC Sickle Cell Trait and Glaucoma Post-Hyphema: Tips to Protect Your Patient's Vision.